Last reviewed · How we verify
depsipeptide
At a glance
| Generic name | depsipeptide |
|---|---|
| Also known as | Romidepsin, Istodax®, FR901228, FK228, Istodax, romidepsin |
| Sponsor | University of Chicago |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Th (Phase 2)
- Romidepsin Therapy in Conditioning and Maintenance in Patients With T-Cell Malignancies Receiving Allogeneic Stem Cell Transplant (Phase 1)
- Phase I Study of Sequential Depsipeptide/Flavopiridol Infusion for Malignancies Involving Lungs, Esophagus, Pleura, Thymus or Mediastinum (Phase 1)
- A Phase II Study Of Depsipeptide, A Histone Deacetylase Inhibitor, In Relapsed Or Refractory Mantle Cell Or Diffuse Large Cell Non-Hodgkin's Lymphoma (Phase 2)
- A Phase I-II Trial of Depsipeptide in Patients With Recurrent High-Grade Gliomas (Phase 1)
- An Exploratory Phase II, Multicenter, Open-label Trial Evaluating the Activity and Tolerability of FK228 in Androgen Independent Metastatic Prostate Cancer Patients With Rising PSA (Phase 2)
- A Phase II Study Of Single Agent Depsipeptide (FK228) In Breast Cancer (Phase 2)
- A Single Agent Phase II Study of Depsipeptide (FK228) in the Treatment of Cutaneous T-cell Lymphoma (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- depsipeptide CI brief — competitive landscape report
- depsipeptide updates RSS · CI watch RSS
- University of Chicago portfolio CI